Wegovy has become one of the most talked-about weight loss medications in the UAE, and for good reason. Approved specifically for chronic weight management, it offers a clinically studied option for people who have struggled to lose weight through diet and exercise alone. But what does Wegovy actually do, who qualifies for it, and what should you realistically expect? This guide covers the essentials.
What Is Wegovy and How Does It Work?
Wegovy is the brand name for semaglutide at a 2.4 mg dose, administered as a once-weekly subcutaneous injection. It belongs to a class of medications called GLP-1 receptor agonists. GLP-1, or glucagon-like peptide-1, is a hormone your body naturally produces after eating. It signals your brain to feel full, slows down how quickly food leaves your stomach, and helps regulate blood sugar.
When you take Wegovy, that natural GLP-1 signal is amplified. The result, for most people, is a meaningful reduction in appetite and food cravings. Patients often describe it as feeling satisfied after smaller portions, without the constant mental battle against hunger.
Wegovy vs Ozempic: Same Molecule, Different Purpose
One of the most common points of confusion is the relationship between Wegovy and Ozempic. Both contain semaglutide. The difference is in their approved indications and dosing.
Ozempic is approved for type 2 diabetes management and is typically dosed between 0.25 mg and 2 mg. Wegovy, on the other hand, is approved specifically for weight management and uses a higher target dose of 2.4 mg. In simple terms, Ozempic was designed for blood sugar control with weight loss as a secondary benefit. Wegovy was designed primarily for weight reduction.
In the UAE, Ozempic is formally prescribed for diabetes or pre-diabetes. If you are looking for a medication approved for obesity management, Wegovy Dubai is the more appropriate option for non-diabetic patients.
What Do the Clinical Trials Show?
The evidence behind Wegovy comes from the STEP trial programme, one of the largest clinical trial series for an anti-obesity medication. In STEP 1, published in the New England Journal of Medicine, participants taking semaglutide 2.4 mg lost an average of about 14.9 percent of their body weight over 68 weeks, compared to 2.4 percent in the placebo group. These participants also received lifestyle counselling alongside the medication.
The SELECT trial added another dimension. This cardiovascular outcomes study, also published in the New England Journal of Medicine, showed that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20 percent in adults with obesity and established cardiovascular disease. That finding was significant because it demonstrated the benefits of Wegovy beyond the scale, specifically for heart health.
In practice, patients can generally expect weight loss in the range of 12 to 15 percent of their starting body weight over 12 months when the medication is combined with consistent lifestyle changes. These are averages. Individual results depend on factors like adherence, nutrition, sleep quality, stress levels, and physical activity.
The Dosing Schedule: Slow and Steady
Wegovy uses a gradual dose escalation over the first 16 weeks. This is intentional. Ramping up slowly gives your body time to adjust and reduces the chance of GI side effects.
The typical schedule looks like this: 0.25 mg for weeks 1 to 4, then 0.5 mg for weeks 5 to 8, then 1 mg for weeks 9 to 12, then 1.7 mg for weeks 13 to 16, and finally the maintenance dose of 2.4 mg from week 17 onward. Your prescribing doctor may adjust this timeline based on how you respond and tolerate each step.
Common Side Effects and What to Expect
The most frequently reported side effects are gastrointestinal: nausea, bloating, constipation, and sometimes diarrhea. These tend to be most noticeable during the dose escalation phase and often improve as the body adjusts over a few weeks.
Nausea is the most common complaint in the early weeks. Eating smaller, protein-focused meals, staying well hydrated, and avoiding overly fatty or greasy foods can help. If nausea persists, the prescribing physician may slow down the dose increase.
Less common but worth noting: some patients experience hair thinning during rapid weight loss. This is usually related to nutrient gaps (particularly protein, iron, zinc, biotin, and B12) rather than the medication itself. Proactive supplementation and adequate protein intake can reduce this risk.
Who Qualifies for Wegovy?
Wegovy is generally prescribed for adults with a body mass index (BMI) of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol.
Before starting, a thorough medical assessment is needed. This typically includes blood tests to check thyroid function, blood sugar, liver enzymes, cholesterol, and key nutrient levels. The goal is to rule out secondary causes of weight gain and to establish a safe baseline before treatment begins.
Wegovy is not suitable for everyone. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take it. Pregnant or breastfeeding women should also avoid it.
Why Lifestyle Changes Still Matter
Wegovy is not a replacement for healthy habits. It is a tool that works best when combined with them. The clinical trials that produced those impressive results included structured lifestyle interventions: better nutrition, regular physical activity, and ongoing counselling.
In real-world practice, the patients who see the best and most lasting results are those who use the appetite reduction from the medication as a window of opportunity. While cravings are lower and portions feel more manageable, it becomes easier to build habits around protein-rich meals, consistent movement, better sleep, and stress management.
This matters because GLP-1 medications address the biological side of appetite and energy regulation. They do not, on their own, change long-term eating patterns or address emotional eating. The lifestyle piece is what helps results stick after the medication is eventually tapered or stopped.
For those exploring medically supervised weight loss with a structured lifestyle component, GLP 1 Dubai can provide the combination of pharmacotherapy and coaching needed for sustainable progress.
Frequently Asked Questions
How long do I need to take Wegovy?
Treatment duration varies. Many patients take it for 12 months or longer. Some may need longer-term use to maintain results, while others transition off the medication after building strong lifestyle habits. This decision is always made with your doctor.
Will I regain weight if I stop Wegovy?
Weight regain is possible when any obesity medication is discontinued. Studies have shown that patients who stop semaglutide without a maintenance plan tend to regain a significant portion of lost weight within a year. That is why building lifestyle habits during treatment is so important.
Is Wegovy the same as Ozempic?
They contain the same molecule (semaglutide) but are approved for different conditions. Wegovy is specifically for chronic weight management at a 2.4 mg dose. Ozempic is for type 2 diabetes at lower doses.
Can I take Wegovy if I am not diabetic?
Yes. Wegovy is specifically approved for weight management in people who are not necessarily diabetic, provided they meet the BMI criteria.
Does Wegovy help with heart health?
The SELECT trial showed a 20 percent reduction in major cardiovascular events in people with obesity and existing heart disease. This is one of the strongest pieces of evidence for cardiovascular benefit from a weight loss medication.
